Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apogee Therapeutics, Inc. (APGE)
NASDAQ:APGE
RESEARCH TOOLSreports
Apogee Therapeutics, Inc. (APGE) Stock Price & Analysis
79 Followers
APGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.19 - $72.29
Previous Close$53.75
Volume484.91K
Average Volume (3M)717.21K
Market Cap
$3.14B
Enterprise Value$2.72B
Total Cash (Recent Filing)$422.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta2.04
Next Earnings
Aug 26, 2024EPS Estimate
-$0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,456,027
10 Day Avg. Volume455,468
30 Day Avg. Volume717,208
Standard Deviation0.35
R-Squared0.25
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)7.71
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$86.75Price Target Upside61.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Apogee Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSanofi's amlitelimab has met its primary endpoint in a Phase 2b study, demonstrating significant reductions in EASI score and durability of response.
Market PotentialFinancial projections for Apogee estimate over $10 billion in sales for APG777 & APG808 based on their superior dosing frequency, with additional upside from potential efficacy superiority.
Product AdvancementAPG777 achieved a 75-day half-life in humans, suggesting potential for less frequent dosing intervals, which could improve patient compliance and convenience.
Bears Say
Market CompetitionThe biggest risk for Apogee is the timing of biosimilar Dupi’s entry into the market, which may impact pricing and reimbursement strategies.
Pricing And ReimbursementThe biggest risk for Apogee is the timing of biosimilar Dupi’s entry into the market, which may impact pricing and reimbursement.
Regulatory ChallengesThe FDA has requested additional subpopulation analyses for Dupixent in COPD which could potentially delay its sBLA approval.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
APGE FAQ
What was Apogee Therapeutics, Inc.’s price range in the past 12 months?
Apogee Therapeutics, Inc. lowest stock price was $14.19 and its highest was $72.29 in the past 12 months.
What is Apogee Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Apogee Therapeutics, Inc.’s upcoming earnings report date?
Apogee Therapeutics, Inc.’s upcoming earnings report date is Aug 26, 2024 which is in 101 days.
How were Apogee Therapeutics, Inc.’s earnings last quarter?
Apogee Therapeutics, Inc. released its earnings results on May 13, 2024. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.587 by -$0.053.
Is Apogee Therapeutics, Inc. overvalued?
According to Wall Street analysts Apogee Therapeutics, Inc.’s price is currently Undervalued.
Does Apogee Therapeutics, Inc. pay dividends?
Apogee Therapeutics, Inc. does not currently pay dividends.
What is Apogee Therapeutics, Inc.’s EPS estimate?
Apogee Therapeutics, Inc.’s EPS estimate is -$0.62.
How many shares outstanding does Apogee Therapeutics, Inc. have?
Apogee Therapeutics, Inc. has 44,969,383 shares outstanding.
What happened to Apogee Therapeutics, Inc.’s price movement after its last earnings report?
Apogee Therapeutics, Inc. reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.587. Following the earnings report the stock price went down -0.921%.
Which hedge fund is a major shareholder of Apogee Therapeutics, Inc.?
Among the largest hedge funds holding Apogee Therapeutics, Inc.’s share is Perceptive Advisors LLC. It holds Apogee Therapeutics, Inc.’s shares valued at 179M.
---
Apogee Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.75 (61.40% Upside)
$86.75 (61.40% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.8%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
---
APGE Stock 12 Month Forecast
Average Price Target
$86.75
▲(61.40% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering APGE
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+91.05%
reiterated a buy rating 5 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +91.05% per trade.
---